E-mail:bd@braincase.cn
Tel:+86 18971216876
English 中文版
Virus Vector - Viral Vector Production - BrainCaseVirus Vector - Viral Vector Production - BrainCase
  • Home
  • Virus product library
    CRISPRRNAiHSV-helperRV-helperNeurophilic virusCalcium imagingOptogenetics activationOptogenetics inhibitionChemical geneticsSparse labelingFluorescent proteinBiosensorsRecombinaseApoptosisDisease ModelNeurotoxicityOther
  • Products Service

    Product Center

    Virus

    AAV Vector Production-Custom AAV-gene therapy vectors-BrainCase
    Lentivirus Vector - Lentivirus Production - BrainCase
    Rabies Virus Vector - RBV Vector - BrainCase
    Herpes Simplex Virus Vector - gene therapy vectors - BrainCase
    PRV
    VSV
    RCAS

    Animal Model

    Neurological Disease Models - Neurological Disorder Models
    Tumor Models - Animal Tumor Models - Model Tumor - BrainCase
    Digestive System Disease Model
    Cardiovascular System Disease Model

    Plasmid Construction

    Regular Plasmid
    Bac
    Library Construction

    Popular Applications

    Gene Regulation

    Gene Overexpression - Gene Overexpression Techniques
    RNA Interference - RNAi Therapeutics - RNAi Therapy - BrainCase
    Gene Editing - Human Gene Editing - Edit Genes - BrainCase

    Neural Circuit Function Research

    Optogenetics - Optogenetics In Humans - BrainCase
    Chemical Genetics - Chemical Genetic Engineering - BrainCase
    Calcium Imaging and Fiber Optic Recording
    GRAB Neurotransmitter Fluorescent Probe
    Functional Magnetic Resonance Imaging Technology

    Research on the structure of neural circuits

    Direct Input and Output-Brain Case
    Anterograde Mono-synaptic Tracing - Brain Case
    Antrograde Muti-synaptic Tracing-Brain Case
    Retrograde Mono-synaptic Tracing-Brain Case
    Retrograde Muti-synaptic Tracing-Brain Case

    Featured Services

    Nervous System Disease Drug Effect

    AD
    Depression
    PD
    Epilepsy

    AAV Serotype Screening

    AAV Serotypes screening - gene therapy - BrainCase

    Tumorigenicity Test

    Tumorigenicity Testing - To Test Tumorigenicity - BrainCase

    Efficacy of Oncolytic Virus

    Oncolytic virus
    Oncolytic Virus Therapy - Herpes Virus Vector - BrainCase
    Oral Stomatitis Virus
  • News
    Corporate News New Product Launch Media Activity Investor News
  • Support
    Literature interpretation Customer article Video Zone FAQs
  • About Us
    Virus product library Products Service News Support About Us Contact
  • Contact
    Contact Us Join us
  • 中文
    English 中文版
  • Home
  • Products Service
  • Featured Services
  • Virus Packaging
  • Virus Packaging
  • AAV
  • LV
  • HSV
  • VSV
  • RCAS

HSV ()

HSV virus production

1. HSV virus amplification

  • 1.1 Resuscitate Vero cells;
  • 1.2 When Vero cells were full grown, they were passaged and inoculated into T75 cell bottle, so that the growth density of the next day was less than 90%;
  • 1.3 Add HSV virus into T75 cell bottle according to a certain amount, and continue to culture in 37℃ 5%CO2 incubator;
  • 1.4 Cytopathic effect was observed continuously from 24 to 72 hours, and the supernatant was collected and stored according to the cytopathic effect.

2 HSV virus concentration

  • 2.1 The stored supernatant was filtered with a 0.22μm filter, and the filtered viral supernatant was centrifuged at 50000g for 2.5h at 4℃.
  • 2.2 After centrifugation, the supernatant was discarded, and the precipitate on the bottom wall of the centrifuge tube was resuspended with an appropriate amount of sterile 1xPBS. The resuspended solution was subjected to sucrose gradient centrifugation at 50000g, 2.5h, and 4℃.
  • 2.3 After centrifugation, the precipitate was resuspended in sterile 1xPBS according to the virus titer.

3 HSV virus titers were measured

  • 3.1 Resuscitate Vero cells;
  • 3.2 When Vero cells were full grown, they were passaged and inoculated into 6-well plates so that the growth density of the next day was less than 90%.
  • 3.3 Take a branch of HSV virus and dilute it 10 times according to the gradient dilution method, generally dilute to 10-9. During the dilution process, the virus solution must be thoroughly mixed and evenly mixed.
  • 3.4 The diluted virus solution was slowly added into the corresponding Wells (two parallel samples), 100ul in each well, and incubated at 37℃ for 1h in a 5%CO2 incubator.
  • 3.5 The culture medium in the 6-well plate was removed by suction, then AGAR medium (1.2% AGAR + maintenance medium) was added, and the culture was continued in a 37℃ 5%CO2 incubator for 48 hours.
  • 3.6 Add neutral red medium (0.33% neutral red + AGAR medium), and continue to culture for 24 hours at 37℃ in 5%CO2 incubator;
  • 3.7 The number of leukoplakia was counted under the naked eye;
  • 3.8 The final virus titer was calculated as titer = number of fluorescence x dilution x10.
map
{dede:global.cfg_webname/}

Virus product library

CRISPR
RNAi
Neurophilic virus
Optogenetics activation
Biosensors

News

Corporate News
New Product Launch
Media Activity
Investor News

Support

Literature interpretation
Customer article
Video Zone
FAQs
Tel: +86 18971216876
E-mail: bd@braincase.cn

Address(Wuhan):Room 409, Unit 1, Building F10, Huazhong Zhigu, Haitang Road, Hanyang District, Wuhan City, Hubei Province

Address(Shenzhen):Building A, Mingzhu Campus, Shenzhen University of Technology, Xinhu Street, Guangming District, Shenzhen City, Guangdong Province

  • Copyright © 2024 Brain Case All Rights Reserved.